TY - JOUR
T1 - Immunogenetics of prostate cancer
T2 - A still unexplored field of study
AU - Dreussi, Eva
AU - Ecca, Fabrizio
AU - Scarabel, Lucia
AU - Gagno, Sara
AU - Toffoli, Giuseppe
PY - 2018/2/1
Y1 - 2018/2/1
N2 - The immune system is a double-edged sword with regard to the prostate cancer (PCa) battle. Immunogenetics, the study of the potential role of immune-related polymorphisms, is taking its first steps in the treatment of this malignancy. This review summarizes the most recent papers addressing the potential of immunogenetics in PCa, reporting immune-related polymorphisms associated with tumor aggressiveness, treatment toxicity and patients' prognosis. With some peculiarities, RNASEL, IL-6, IL-10, IL-1β and MMP7 have arisen as the most significant biomarkers in PCa treatment and management, having a potential clinical role. Validation prospective clinical studies are required to translate immunogenetics into precision treatment of PCa.
AB - The immune system is a double-edged sword with regard to the prostate cancer (PCa) battle. Immunogenetics, the study of the potential role of immune-related polymorphisms, is taking its first steps in the treatment of this malignancy. This review summarizes the most recent papers addressing the potential of immunogenetics in PCa, reporting immune-related polymorphisms associated with tumor aggressiveness, treatment toxicity and patients' prognosis. With some peculiarities, RNASEL, IL-6, IL-10, IL-1β and MMP7 have arisen as the most significant biomarkers in PCa treatment and management, having a potential clinical role. Validation prospective clinical studies are required to translate immunogenetics into precision treatment of PCa.
KW - immune system
KW - polymorphisms
KW - prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85041696310&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041696310&partnerID=8YFLogxK
U2 - 10.2217/pgs-2017-0163
DO - 10.2217/pgs-2017-0163
M3 - Review article
C2 - 29325503
AN - SCOPUS:85041696310
VL - 19
SP - 263
EP - 283
JO - Pharmacogenomics
JF - Pharmacogenomics
SN - 1462-2416
IS - 3
ER -